For prescribing information and adverse event reporting, click here

This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here

This website has been commissioned by Ipsen UK and is intended for a UK audience.

Resources

Paediatric Spasticity

Paediatric Spasticity - Resources
Paediatric Spasticity - Resources

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) therapeutic indications

Dysport® is indicated for symptomatic treatment of focal spasticity of:

  • Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older
  • Upper limbs in paediatric cerebral palsy patients, two years of age or older.

Please click here to see the full therapeutic indications.

Product Resources

Clinical trials for Dysport (Clostridium botulinum type A toxin-haemagglutinin complex) for focal upper and lower limb spasticity in Children with Cerebral Palsy.
Clinical trials for Dysport (Clostridium botulinum type A toxin-haemagglutinin complex) for focal upper and lower limb spasticity in Children with Cerebral Palsy.
PDF / PowerPoint Deck 57 pages

An overview of the phase 3 clinical trials of Dysport (Clostridium botulinum type A toxin-haemagglutinin complex) in children with cerebral palsy with upper and lower limb focal spasticity.

DYS-UK-009051 | November 2024
Injection Handbook – Paediatric Spasticity
Injection Handbook – Paediatric Spasticity
PDF / PowerPoint Deck 52 pages

A reference guide to the administration of Dysport (Clostridium botulinum type A toxin-haemagglutinin complex) for the treatment of focal spasticity of upper and lower limbs in paediatric cerebral palsy patients, two years of age or older, including the identification of muscles using ultrasound, and the recommended injection technique per muscle

DYS-UK-009020 | November 2024
Dose Map for Paediatric Spasticity
Dose Map for Paediatric Spasticity
PDF / PowerPoint Deck 3 pages

A downloadable reference guide to the dosing of Dysport (Clostridium botulinum type A toxin-haemagglutinin complex) for treatment of focal spasticity of upper and lower limbs in paediatric cerebral palsy patients, two years of age or older.

DYS-UK-008961 | November 2024
Dilution Guide
Dilution Guide
PDF / PowerPoint Deck 2 pages

A reference guide to reconstituting and diluting Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) .

DYS-UK-009018 | November 2024
Reconstitution Guide
Reconstitution Guide
Video 10:03

How to prepare, reconstitute and store Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex).

DYS-UK-009047 | November 2024
Mechanism of Action of Botulinum Neurotoxin Type A
Mechanism of Action of Botulinum Neurotoxin Type A
Video 3:13

Short animation explaining the mechanism of action of botulinum neurotoxin type A

DYS-UK-009022 | November 2024

eLearning

Overview of Paediatric Spasticity – eLearning Module
Overview of Paediatric Spasticity – eLearning Module
PDF / PowerPoint Deck 41 pages

An overview of spasticity in children, including the classification of cerebral palsy and its consequences.

DYS-UK-009168 | November 2024
Goal Setting for Children with Spasticity
Goal Setting for Children with Spasticity
PDF / PowerPoint Deck 64 pages

An overview of goal setting for children with spasticity including the Canadian Occupation Performance Measure (COPM) and Goal Attainment Scaling (GAS).

DYS-UK-009106 | November 2024
Goal Setting in Spastic Paresis
Goal Setting in Spastic Paresis
Video 30:31

Presented by: Dr Nigar Dursun

DYS-UK-009243 | November 2024

Talking Head Videos

Demystifying the Clinical Relevance of BoNT Immunogenicity
Demystifying the Clinical Relevance of BoNT Immunogenicity
Video 06:00

Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment. Presented by: Dr Tim Harrower.

DYS-UK-009026 | November 2024

Contact your Ipsen representative

Send request
Resources

To access relevant information about Paediatric Spasticity, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only.
Contains promotional information

I am a UK Healthcare Professional

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 
01753 627777.

I am a member of the general public

This section is for members of the general public.

I am a member of the general public